期刊簡介 | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | Cancer Discovery LetPub Score 9.3
50 ratings
Rate
Reputation 10.0 Influence 9.3 Speed 7.0 | ||||||||||||||||
期刊簡稱 | CANCER DISCOV | ||||||||||||||||
ISSN | 2159-8274 | ||||||||||||||||
E-ISSN | 2159-8290 | ||||||||||||||||
h-index | 119 | ||||||||||||||||
CiteScore |
| ||||||||||||||||
自引率 (2023-2024) | 1.00%自引率趨勢 | ||||||||||||||||
掲載範囲 |
| ||||||||||||||||
官方網站 | http://cancerdiscovery.aacrjournals.org/ | ||||||||||||||||
在線稿件提交 | https://cd.msubmit.net/cgi-bin/main.plex | ||||||||||||||||
開放訪問 | No | ||||||||||||||||
出版商 | American Association for Cancer Research Inc. | ||||||||||||||||
主題領域 | ONCOLOGY | ||||||||||||||||
出版國/地區 | UNITED STATES | ||||||||||||||||
發行頻率 | |||||||||||||||||
創刊年 | 2011 | ||||||||||||||||
每年文章數 | 117每年文章數趨勢 | ||||||||||||||||
黃金OA百分比 | 36.96% | ||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q1
| ||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2159-8274%5BISSN%5D | ||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Slow, 6-12 Week(s) | ||||||||||||||||
競爭力 * | 來自作者的數據: Very difficult | ||||||||||||||||
參考鏈接 |
| ||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
首頁 上一頁 1 2 下一頁 末頁 (頁 | |
[Cancer Discovery] 的評論 | 撰寫評論 |
作者: Martha Jacob 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-09 09:17:52 評論於 There are differences here, not just looking at the impact factor. All three journals are top level, there is no doubt about that. It is said here that Cancer Cell is the big brother, mainly because of the contributions of big shots who are doing cancer research around it. Generally speaking, if an article has enough information, CC is usually the first choice. Also, in terms of industry reputation, CC has been established for more than 20 years. Compared to Nature Cancer and Cancer Discovery, there is no doubt that it is the big brother. It has nothing to do with the impact factor, and even looking at IF, CC is currently the highest(0) 讚! | Martha Jacob |
作者: 是志丹吖 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-07 18:49:54 評論於 They should be similar, the three mainstream publications are also similar. Although the impact factor is different, it does not mean that one is better than the other! They are all top-notch. Just like the articles published in Science are not necessarily worse than in Nature, it is just that some authors prefer one over the other, and the article numbers are slightly different. They are all top-notch(0) 讚! | 是志丹吖 |
作者: 太山嘉懿 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-07 16:14:11 評論於 Why are Impact Factors of Science and AACR so high (The editor is of Chinese descent)? Cell and Nature are both commercial, while Science and AACR have always maintained their academic independence(0) 讚! | 太山嘉懿 |
作者: 是志丹吖 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-07 09:36:26 評論於 Cancer cells are also transitioning and starting to include clinical articles, which may lead to an increase in impact factor(0) 讚! | 是志丹吖 |
作者: Martha Jacob 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-09-15 21:10:41 評論於 Magazines at this level, whether slightly higher or lower in impact factor, no longer make any difference(0) 讚! | Martha Jacob |
作者: Martha Jacob 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-09-13 21:07:38 評論於 Submission hit rate: 5.0 Sharing experience: It feels like Cancer Cell, Cancer Discovery, and Nature Cancer will form a tripartite alliance in the future. As of now, Cancer Cell remains the undisputed leader(0) 讚! | Martha Jacob |
作者: 重阳悦爱 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-09-01 09:35:04 評論於 Review speed: 1.0 | Submission acceptance rate: 25.0 Emphasized research direction: Medical experience sharing: More focused on clinical aspects, not bad, but in comparison, there is a gap in article quality compared to Cancer Cell(0) 讚! | 重阳悦爱 |
作者: mingq w 領域: 生物学 審稿時間: 2.0 month(s) 結果: 修改後接受 撰寫評論 |
2023-04-16 23:58:15 評論於 Extremely authoritative journal(1) 讚! | mingq w |
作者: 血天谷云 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-01-09 23:18:51 評論於 22 years later, CC is ahead again. His pitch was rejected, so he tried his luck with CD(0) 讚! | 血天谷云 |
作者: 血天谷云 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-06-09 22:51:10 評論於 In 2021, CD is 39.397, CC is 31.743(0) 讚! | 血天谷云 |
作者: 龙鳞尚萍 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-06-09 19:37:39 評論於 Before Cancer Cell discovered cancer, you've got it wrong. I've noticed that articles in CD have been lower than CC in recent years, and this year in 2022, the score for CC is higher than CD(0) 讚! | 龙鳞尚萍 |
作者: 血天谷云 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-06-09 17:09:54 評論於 The IF of CD has been higher than CC for several years, so please investigate it carefully(0) 讚! | 血天谷云 |
作者: 血天谷云 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-05-26 22:09:32 評論於 Top journal! It is ranked ahead of cancer cell. Hope to complete the work in the second half of the year and give it a try for publication(0) 讚! | 血天谷云 |
作者: 太山嘉懿 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-01-12 22:13:11 評論於 Your attitude is really good!(0) 讚! | 太山嘉懿 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 20:06:42 評論於 The Importance of Exercise in Maintaining Overall Health(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 10:57:13 評論於 Make a list of the most important keywords; come up with a title that includes all the vocabulary; remove unnecessary/repetitive words and link the remaining words; rewrite the title after deleting non-essential information(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 平原文波 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-28 16:58:23 評論於 Is there a trick to writing article titles?(0) 讚! | 平原文波 |
作者: 北国博达 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-27 15:21:52 評論於 How to Write a Better Article Title?(0) 讚! | 北国博达 |
作者: 法慧佳文 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-08-04 16:23:35 評論於 Review speed: 1.0 | Submission hit rate: 5.0 Experience sharing: In the field of blood, I submitted a paper and it was rejected in one week. The reason was that some papers had already been published in this field before, and the level of innovation was lacking a bit. However, it was recommended to submit to Blood Cancer Discovery, a new journal under AACR, with top quality articles, but currently without impact factor. I eventually gave up on resubmitting. In short, there is little hope if there is a lack of innovation. The layout of the magazine is really beautiful, with exquisite articles on the front page(0) 讚! | 法慧佳文 |
作者: 重阳文景 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2018-07-03 13:11:31 評論於 I have been following this magazine for a long time. The quality of the articles they publish is indeed very high. It is not easy for ordinary people to get published. To publish, you really need to have good ideas and conduct detailed research on the mechanism(0) 讚! | 重阳文景 |
作者: 重阳文景 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2018-06-30 19:10:35 評論於 It is indeed a very classic magazine(0) 讚! | 重阳文景 |
作者: Bevis Bart 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2018-05-18 14:45:50 評論於 Really like the layout of this magazine. It mostly features articles on current hot topics, making it difficult for niche studies to be published(0) 讚! | Bevis Bart |
作者: 重阳文景 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2018-05-09 13:46:59 評論於 I really want to publish a paper in this journal!! There are only over 80 articles published in a year. It must be difficult to get accepted(0) 讚! | 重阳文景 |
作者: 无击幻玉 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2018-01-09 08:55:21 評論於 Only over 80 articles in a year, it must be difficult to pitch(0) 讚! | 无击幻玉 |
作者: Emmanuel Katte 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-09-28 13:27:27 評論於 This magazine is too slow, it's been a month and still in submission status?(0) 讚! | Emmanuel Katte |
首頁 上一頁 1 2 下一頁 末頁 (頁 |
Contact us